PAVmed Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Agreements Related to Acquired Intellectual Property Rights (Details Narrative)

Agreements Related to Acquired Intellectual Property Rights (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Jun. 21, 2019	May 12, 2018	Jun. 30, 2018	Jun. 28, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2016
Accrued expenses and other current liabilities					$ 1,386,773	$ 1,330,746
Employee stock purchase plan					82,772
Lucid Diagnostics Inc [Member]
Shares of common stock percentage					81.875%	81.875%
Contract Development and Manufacturing Organization [Member]
Number of units to purchase order			$ 5,000
Payment to third-party			$ 50,000
EsoGuard License Agreement [Member] \| Lucid Diagnostics Inc [Member]
Reimbursement amount		$ 273,000
License fee as an initial requirement		50,000
Initial payment of intellectual property		$ 50,000
Description of intellectual property payment		Quarterly payments of $50,000 until such fee is paid-in-full, provided, however, the commencement of such quarterly payments is subject to Lucid Diagnostics Inc. consummation of a bona fide financing with an unrelated third-party in excess of $500,000.
Accrued expenses and other current liabilities					$ 222,553
Milestone payment	$ 75,000
Agreement description	The license agreement also provides for two additional milestone obligations with a payment of $100,000 due within 30 days upon the first commercial sale of a licensed product and a payment of $200,000 due upon a PMA submission to the FDA related to a licensed product.
Description of equity interest percentage		The right, in its sole discretion, to require the Company to transfer to CWRU a percentage, varying up to 100%, of the shares of common stock of Lucid Diagnostics Inc.
Shares of common stock percentage		100.00%
EsoCheck License Agreement[Member] \| Research and Development Expenses [Member]
Reimbursement of patent fees					200,437	$ 20,978
Consulting Agreements [Member] \| 2014 Long-Term Incentive Plan [Member] \| Parent Company [Member]
Employee stock purchase plan		25,000
Exercise price per share of common stock		$ 1.59
Consulting Agreements [Member] \| Lucid Diagnostics Inc [Member] \| 2018 Long-Term Incentive Equity Plan [Member]
Employee stock purchase plan		100,000
Exercise price per share of common stock		$ 0.50
Consulting Agreements [Member] \| Contract Development and Manufacturing Organization [Member]
Employee stock purchase plan				75,000
Exercise price per share of common stock				$ 1.00
Tufts Patent License Agreement [Member]
Non-refundable fees							$ 50,000
Tufts Patent License Agreement [Member] \| Research and Development Expenses [Member]
Reimbursement of patent fees					$ 70,996	$ 113,688